Be(a)ware of Leukocytosis in Papillary Thyroid Cancer

Styliani Laskou,1 Konstantinos Sapalidis,1 Christos Topalidis,2 Triantafyllia Koletsia,2 and Isaak Kesisoglou1

13rd Surgical Department, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece
2Department of Pathology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Correspondence should be addressed to Styliani Laskou; stelaskou@gmail.com

Received 8 February 2022; Revised 5 June 2022; Accepted 30 June 2022; Published 16 July 2022

Copyright © 2022 Styliani Laskou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Leukocytosis can be present at any time during various malignancies. A 42-year-old male was admitted to our department for surgical management of his metastatic papillary thyroid cancer. Persistent white blood cell (WBC) elevation with left shift led to a thorough investigation. Having excluded other causes, leukocytosis was attributed to thyroid cancer itself. Positive immunostaining for IL-6 and CEA, as well as elevated serum levels, established this connection.

1. Introduction

Tumor-related leukocytosis is associated with advanced tumor-stage and poor patient outcomes. However, it has been largely ignored or misinterpreted. If the underlying malignancy is not clinically evident, leukocytosis could be attributed to myeloproliferative neoplasms, misleading the patient’s management. Solid tumors such as lung, genitourinary, gastrointestinal, melanoma, and head and neck may secrete cytokines, mainly granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), and/or interleukins. As far as thyroid cancer is concerned, squamous and anaplastic cancer cases associated with leukocytosis have been reported. We report the rare case of a well-differentiated papillary thyroid carcinoma linked to neoplastic leukocytosis and elevated CEA levels.

2. Case Report/Case Presentation

In February 2021, a 42-year-old male was admitted to our surgical department due to metastatic papillary thyroid carcinoma detected on an outpatient investigation. He had previously visited a maxillofacial surgeon due to palpable right neck lymphadenopathy, who suggested a neck ultrasound (US). The US showed a 21 × 12 mm hypoechoic solid lesion in the thyroid isthmus and a 33 × 32 × 25 mm lesion with abnormal parenchymal composition and calcifications occupying the right lobe. Central and right lateral cervical lymph nodes were highly suspicious. Fine needle aspiration of the two tumors and a region III lymph node suggested the presence of a metastatic multifocal papillary thyroid carcinoma (PTC).

Thyroid function examination and anti-thyroglobulin antibodies were within the normal range while serum thyroglobulin was 176.9 ng/ml (normal range: 0–50 ng/ml). It was noteworthy that his laboratory tests showed leukocytosis with neutrophilia (WBC: 21,390 K/μl, NE: 18,300 K/μl), although further investigation was not considered. The patient underwent thyroidectomy with central and right lateral selective lymph node dissection. Due to the aggressive behavior of the tumor, the right thyroid lobe and specimens from the trachea were sent for intraoperative histologic examination, which confirmed the presence of PTC in the right lobe and neoplastic infiltration of the fibroadipose tissue from the trachea along with a metastatic lymph node. The operation was completed, and the patient had an uneventful recovery.

Gross examination of the thyroid specimen revealed multiple white to tan nodules scattered throughout the gland, both in the lobes, but also in the isthmus, measured...
from 0.2 cm to 5 cm in diameter. Hematoxylin and eosin-stained sections showed that the described lesions correspond to PTC characterized mainly by papillary structures “(shown in Figure 1(a))”. The lining epithelium consisted of medium-sized cells with eosinophilic cytoplasm and distinctive nuclear features, namely, nuclear overlapping, chromatin clearing, irregular nuclear contour, and nuclear grooves and pseudoinclusions “(shown in Figure 1(b))”. Psammoma bodies were also present in the adjacent area. Stroma was fibrous with dense collagenous with sparsely inflammatory cells. Despite the multiple sections, areas of low differentiation or anaplastic features were not observed. Cancer cells invaded the thyroid capsule and expanded in the surrounding tissues. In addition, seven cervical lymph nodes displayed metastases from the carcinoma. Histologic findings were consistent with a multifocal PTC of the classic type. The surrounding tissues, in addition, seven cervical lymph nodes displayed metastases from the carcinoma. Histologic examination revealed positivity in a few neoplastic cells “(shown in Figure 2(a))”. Few cells were immunoreactive to CEA antibody as well “(shown in Figure 2(b))”.

Postoperatively, he received a dose of 120 mCi iodine 131. Whole-body scan showed foci of uptake in the thyroid bed. Appropriate thyroxine suppressive therapy was added and on the second post-iodine month patient new examinations were ordered revealing normalized levels of TSH and TG (0.8 μU/ml and 131 ng/ml respectively). Surprisingly, WBC and neutrophils, ESR, CRP, and CEA were also within the normal range (WBC: 9800 K/μL, NE: 5000 K/μL, ESR:12, CRP:0.5, CEA: 1.2). IL-6 levels were also measured (2.8 pg/ml). The patient remains under close endocrinologic and surgical surveillance without evidence of recurrence.

3. Discussion

This patient may represent the first established classic papillary thyroid carcinoma case with associated leukocytosis and elevated CEA levels caused by IL-6 and CEA expression by tumor cells. Leukocytosis and malignancy have long been linked and known as paraneoplastic leukemoid reaction [1]. In its formal definition, leukemoid reaction refers to persistent leukocytosis (WBC > 40 000/μL) in the absence of a hematologic malignancy. Various infections, intoxications, malignancies, severe hemorrhage, or acute hemolysis may be the etiology [2]. Paraneoplastic leukemoid reaction occurs in the presence of a non-malignant cytokine-secreting tumor and in the absence of bone marrow infiltration by that tumor [3]. In many malignancies, a less profound leukocytosis may be observed, although.

It seems that irregular cytokine production by tumor cells, such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukins (IL-3, IL-6, and TNF-α) initiate the pathogenesis [4] leading to granulocytosis. This ability may be present along with tumor development or secondarily after dedifferentiation and can also be seen in metastatic sites even if it is absent in the primary tumor [5]. Cytokine-producing tumor foci grow faster than the nonproducing ones due to an autocrine growth induction phenomenon [6]. In addition to stimulating bone marrow granulocytosis, an inhibition of myeloid cell differentiation in the tumor microenvironment may be observed, causing the accumulation of immature myeloid cells. These myeloid-derived suppressor cells “protect” the tumor, contributing also to neoangiogenesis and cancer progression. Such patients seem to have a poor prognosis [3].

A variety of tumors may be associated with elevated WBC. Tumor-related leukocytosis may be present at any time during the disease, simultaneously, late, or even prior to the diagnosis. Although lung and kidney malignancies are commonly associated with leukocytosis, gastrointestinal, hepatobiliary, genitourinary, melanoma, and head and neck cancers [2] have also been reported.

Thyroid malignancies have also been associated with paraneoplastic leukocytosis. Two cases of squamous cell carcinoma [7, 8] and seventeen cases of anaplastic tumor have been reported [9–23]. Both cases of squamous cell carcinoma were related to marked leukocytosis and hypercalcemia. The authors proposed that tumor cells produced G-CSF, IL-1α, and PTH-rP, suggesting the existence of a new paraneoplastic syndrome. Elevated G-CSF levels were detected in anaplastic thyroid cancer cases. Only a few case reports evaluated IL-6 levels as either elevated or within the normal range [10–12, 23].

A unique case of aggressive papillary thyroid cancer associated with neutrophilia has been published.
Vassilatou et al. hypothesized that the presence of CSF-producing tumor was indicated by elevated GM-CSF serum levels. Bone marrow biopsy revealed infiltration by the papillary thyroid carcinoma [24]. Our patient differed from the above since the tumor cells synthesized and secreted IL-6, which seemed to be the cause of leukocytosis. Perhaps, both cases indicate papillary thyroid cancer as a precursor of anaplastic.

Moreover, tumor cells were positive for CEA with elevated CEA serum levels. CEA is produced as an expression of CEA-related cell adhesion molecule 5 gene and is found in 90% of gastrointestinal cancers, 70% of lung cancers, and 50% of breast cancers [25]. Elevated levels may also be seen in ovarian cancer, appendix, mucinous cystadenoma, and medullary thyroid carcinoma. Since only single cases of CEA-positive papillary thyroid cancer have been observed, its significance remains uncertain.

4. Conclusion

Tumor-related leukocytosis is associated with tumor aggressiveness and probably poor prognosis. When dealing with patients with unexplained leukocytosis, a high level of suspicion is required for this entity.

Data Availability

The datasets used during the current study are available from the corresponding author on reasonable request.

Additional Points

Tumor-related leukocytosis could represent a form of paraneoplastic syndrome caused by cytokine secretion from tumor cells.

Consent

The patient has given written informed consent to publish this case including the publication of images.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

S.L. perceived the idea, collected the samples, processed the data, drafted the manuscript, and designed the figures. K.S. was involved in planning and supervised the work. T.K. and C.T. performed the histopathological analysis and designed
the histopathologic figures. I.K. was the supervising physician. All authors discussed the results and commented on the manuscript.

References

[1] S. Asano, A. Urabe, T. Okabe, N. Sato, and Y. Kondo, "Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue," *Blood*, vol. 49, no. 5, pp. 845–852, 1977.

[2] V. Sakka, S. Tsiodras, E. J. Giamarellos-Bourboulis, and H. Giamarellou, "An update on the etiology and diagnostic evaluation of a leukemoid reaction," *European Journal of Internal Medicine*, vol. 17, no. 6, pp. 394–398, 2006.

[3] I. A. Abukhiran, J. Jasser, and S. Syrbi, "Paraneoplastic leukemoid reactions induced by cytokine-secreting tumours," *Journal of Clinical Pathology*, vol. 73, no. 6, pp. 310–313, 2020.

[4] J. M. Granger and D. P. Kontoyiannis, "Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study," *Cancer*, vol. 115, no. 17, pp. 3919–3923, 2009.

[5] R. A. Wilcox, "Cancer-associated myeloproliferation: old association, new therapeutic target," *Mayo Clinic Proceedings*, vol. 85, no. 7, pp. 656–663, 2010.

[6] I. Kasuga, S. Makino, H. Kiyokawa, H. Katoh, Y. Ebihara, and K. Ohyashiki, "Tumor-Related leukocytosis is linked with poor prognosis in patients with lung carcinoma," *Cancer*, vol. 92, no. 9, pp. 2399–2405, 2001.

[7] K. Saito, Y. Kuratomi, K. Yamamoto et al., "Primary squamous cell carcinoma of the thyroid associated with marked leukocytosis and hypercalcemia," *Cancer*, vol. 48, no. 9, pp. 2080–2083, 1981.

[8] P. E. Riddle and H. P. Dinscy, "Primary squamous cell carcinoma of the thyroid associated with leukocytosis and hypercalcemia," *Archives of Pathology & Laboratory Medicine*, vol. 111, no. 4, pp. 373–374, 1987.

[9] T. Fujita, Y. Ogawara, M. Naito, H. Doihara, and N. Shimizu, "Anaplastic thyroid carcinoma associated with granulocyte colony-stimulating factor: report of a case," *Surgery Today*, vol. 36, no. 1, pp. 63–67, 2005.

[10] J. S. Saitoh, A. Musha, T. Mizukami, T. Abe, and T. Nakano, "A case of thyroid anaplastic carcinoma presenting marked neutrophilia and eosinophilia due to co-production of GM-CSF, M-CSF and IL-6," *International Journal of Radiology & Radiation Therapy*, vol. 3, no. 2, pp. 203–206, 2017.

[11] T. Sato, M. Omura, J. Saito et al., "Neutrophilia associated with anaplastic carcinoma of the thyroid: production of macrophage colony-stimulating factor (M-CSF) and Interleukin-6," *Thyroid*, vol. 10, no. 12, pp. 1113–1118, 2000.

[12] S. Yazawa, H. Toshimori, K. Nakatsuru, H. Katakami, J. Takemura, and S. Matsukura, "Thyroid anaplastic carcinoma producing granulocyte-colony-stimulating factor and parathyroid hormone-related protein," *Internal Medicine*, vol. 34, no. 6, pp. 584–588, 1995.

[13] H. Murabe, T. Akamizu, A. Kubota, and S. Kusaka, "Anaplastic thyroid carcinoma with prominent cardiac metastasis, accompanied by a marked leukocytosis with a neutrophilia and high GM-CSF level in serum," *Internal Medicine*, vol. 31, no. 9, pp. 1107–1111, 1992.

[14] K. Iwasa, M. Noguchi, K. Mori et al., "Anaplastic thyroid carcinoma producing the granulocyte colony stimulating factor (G-CSF): report of a case," *Surgery Today*, vol. 25, no. 2, pp. 158–160, 1995.

[15] T. Nakada, H. Sato, F. Inoue, F. Mizorogi, K. Nagayama, and T. Tanaka, "The production of colony-stimulating factors by thyroid carcinoma is associated with marked neutrophilia and eosinophilia," *Internal Medicine*, vol. 35, no. 10, pp. 815–820, 1996.

[16] S. Hoshi, A. Yoshizawa, H. Arioka, N. Kobayashi, K. Kudo, and H. Niino, "Anaplastic thyroid carcinoma with lung metastasis producing CA 19-9 and GM-CSF," *Nihon Kogyuki Gakkai Zasshi*, vol. 38, no. 5, pp. 391–397, 2000.

[17] T. Kitanishi, M. Suzuki, J. Fukui et al., "Two cases of thyroid carcinoma producing granulocyte colony-stimulating factor," *Journal of Otolaryngology*, vol. 29, no. 3, pp. 174–178, 2000.

[18] M. Zweifel, F. Stenner-Liewen, A. Weber et al., "Increased bone marrow activity on F-18-FDG PET/CT in granulocyte colony stimulating factor producing anaplastic thyroid carcinoma," *Clinical Nuclear Medicine*, vol. 35, no. 2, pp. 103–104, 2010.

[19] R. Nakayama, K. Horiuchi, M. Susa et al., "Anaplastic transformation of follicular thyroid carcinoma in a metastatic skeletal lesion presenting with paraneoplastic leukocytosis," *Thyroid*, vol. 22, no. 2, pp. 200–204, 2012.

[20] K. Kang, J. H. Park, J. Y. Ryu, S. Y. Lee, G. J. Ko, and Y. J. Kwon, "Acute pyelonephritis with anaplastic thyroid carcinoma producing granulocyte colony-stimulating factor," *Blood Research*, vol. 48, no. 1, pp. 63–66, Mar. 2013.

[21] H. R. Lee, J. S. Baek, S. H. Lee, A. R. Cho, J. Y. Lee, and J. M. Jang, "Paraneoplastic neutrophilia originating from an anaplastic transformation of papillary thyroid carcinoma in a metastatic pleural lesion," *Medical Journal of Chosun University*, vol. 39, no. 1, pp. 39–42, 2014.

[22] J. Shiraiishi, H. Koyama, M. Seki et al., "Anaplastic thyroid carcinoma accompanied by uncontrollable eosinophilia," *Internal Medicine*, vol. 54, no. 6, pp. 611–616, 2015.

[23] A. Polymeris, C. Kogia, D. Ioannidis et al., "Excessive leukocytosis leading to a diagnosis of aggressive thyroid anaplastic carcinoma: a case report and relevant review," *The European Thyroid Journal*, vol. 9, no. 3, pp. 162–168, 2020.

[24] E. Vassilatou, M. Fisfis, G. Morphopoulos et al., "Papillary thyroid carcinoma producing granulocyte-macrophage colony-stimulating factor is associated with neutrophilia and eosinophilia," *Hormones*, vol. 5, no. 4, pp. 303–309, 2006.

[25] K. Wakabayashi-Nakao, K. Hatakeyama, K. Oshihama, K. Ken Yamaguchi, and T. Mochizuki, "Carcinoembryonic antigen-related cell adhesion molecule 4 (CEACAM4) is specifically expressed in medullary thyroid carcinoma cells," *Biomedical Research*, vol. 35, no. 4, pp. 237–242, 2014.